These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 23474756)

  • 21. Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?
    Janning M; Ben-Batalla I; Loges S
    Expert Rev Hematol; 2015 Apr; 8(2):135-8. PubMed ID: 25578023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells.
    Zheng R; Levis M; Piloto O; Brown P; Baldwin BR; Gorin NC; Beran M; Zhu Z; Ludwig D; Hicklin D; Witte L; Li Y; Small D
    Blood; 2004 Jan; 103(1):267-74. PubMed ID: 12969963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase.
    Keating AK; Salzberg DB; Sather S; Liang X; Nickoloff S; Anwar A; Deryckere D; Hill K; Joung D; Sawczyn KK; Park J; Curran-Everett D; McGavran L; Meltesen L; Gore L; Johnson GL; Graham DK
    Oncogene; 2006 Oct; 25(45):6092-100. PubMed ID: 16652142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme.
    Knubel KH; Pernu BM; Sufit A; Nelson S; Pierce AM; Keating AK
    Oncotarget; 2014 Mar; 5(5):1338-51. PubMed ID: 24658326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112.
    Yang X; Liu L; Sternberg D; Tang L; Galinsky I; DeAngelo D; Stone R
    Cancer Res; 2005 Aug; 65(16):7338-47. PubMed ID: 16103085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
    Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
    Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RhoA/phosphatidylinositol 3-kinase/protein kinase B/mitogen-activated protein kinase signaling after growth arrest-specific protein 6/mer receptor tyrosine kinase engagement promotes epithelial cell growth and wound repair via upregulation of hepatocyte growth factor in macrophages.
    Lee YJ; Park HJ; Woo SY; Park EM; Kang JL
    J Pharmacol Exp Ther; 2014 Sep; 350(3):563-77. PubMed ID: 24939420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.
    Drexler HG
    Leukemia; 1996 Apr; 10(4):588-99. PubMed ID: 8618433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation.
    Hartman AD; Wilson-Weekes A; Suvannasankha A; Burgess GS; Phillips CA; Hincher KJ; Cripe LD; Boswell HS
    Exp Hematol; 2006 Oct; 34(10):1360-76. PubMed ID: 16982329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations.
    Robinson LJ; Xue J; Corey SJ
    Exp Hematol; 2005 Apr; 33(4):469-79. PubMed ID: 15781338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.
    Smith BD; Levis M; Beran M; Giles F; Kantarjian H; Berg K; Murphy KM; Dauses T; Allebach J; Small D
    Blood; 2004 May; 103(10):3669-76. PubMed ID: 14726387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PPM1D Knockdown Suppresses Cell Proliferation, Promotes Cell Apoptosis, and Activates p38 MAPK/p53 Signaling Pathway in Acute Myeloid Leukemia.
    Li B; Hu J; He D; Chen Q; Liu S; Zhu X; Yu M
    Technol Cancer Res Treat; 2020; 19():1533033820942312. PubMed ID: 32691668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SYK regulates mTOR signaling in AML.
    Carnevale J; Ross L; Puissant A; Banerji V; Stone RM; DeAngelo DJ; Ross KN; Stegmaier K
    Leukemia; 2013 Nov; 27(11):2118-28. PubMed ID: 23535559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Expression of Mer on Jurkat cells and its anti-apoptosis effect].
    Fan L; Dai L; Shen F; Zhou MY; Dong NZ; Ruan CG
    Ai Zheng; 2007 Jul; 26(7):698-702. PubMed ID: 17626743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival.
    Kim KT; Baird K; Ahn JY; Meltzer P; Lilly M; Levis M; Small D
    Blood; 2005 Feb; 105(4):1759-67. PubMed ID: 15498859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
    Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
    Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia.
    Zeng Z; Samudio IJ; Zhang W; Estrov Z; Pelicano H; Harris D; Frolova O; Hail N; Chen W; Kornblau SM; Huang P; Lu Y; Mills GB; Andreeff M; Konopleva M
    Cancer Res; 2006 Apr; 66(7):3737-46. PubMed ID: 16585200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GAS6/Mer axis regulates the homing and survival of the E2A/PBX1-positive B-cell precursor acute lymphoblastic leukemia in the bone marrow niche.
    Shiozawa Y; Pedersen EA; Taichman RS
    Exp Hematol; 2010 Feb; 38(2):132-40. PubMed ID: 19922767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice.
    Piloto O; Levis M; Huso D; Li Y; Li H; Wang MN; Bassi R; Balderes P; Ludwig DL; Witte L; Zhu Z; Hicklin DJ; Small D
    Cancer Res; 2005 Feb; 65(4):1514-22. PubMed ID: 15735040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.
    Jiang J; Paez JG; Lee JC; Bo R; Stone RM; DeAngelo DJ; Galinsky I; Wolpin BM; Jonasova A; Herman P; Fox EA; Boggon TJ; Eck MJ; Weisberg E; Griffin JD; Gilliland DG; Meyerson M; Sellers WR
    Blood; 2004 Sep; 104(6):1855-8. PubMed ID: 15178581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.